Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong takes Proactive’s Elisha Newell through an Investigational New Drug (IND) approval for the company’s first-in-class onCARlytics clinical trial. The IND greenlight, granted by the US Food and Dug Administration, allows Imugene to start patient recruitment and dosing for a Phase 1 study in adults with advanced or metastatic solid tumours. Chong sees the approval as a crucial step forward as clinicians and patients combat solid tumour cancers, which to date have evaded treatment with CD19- targeting biological drugs.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
